Organization
Melvin and Bren Simon Cancer Center, Indianapolis, IN
4 abstracts
Abstract
RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).Org: Cancer Research @UCC, Cork, Ireland, Lineberger Comprehensive Center, Chapel Hill, NC, University of California, San Francisco, CA, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD,
Abstract
Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors.Org: Indiana University – Purdue University Indianapolis, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indianapolis, IN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,
Abstract
Clinical outcomes in patients with post-chemotherapy residual non-retroperitoneal (RP) disease in non-seminomatous germ-cell tumors (NSGCT).Org: Indiana University – Purdue University Indianapolis, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Department of Hematology/Oncology,
Abstract
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Indiana University Simon Cancer Center and Roudebush VAMC, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center, Melvin and Bren Simon Cancer Center, Indianapolis, IN,